A Multi-center, Open, phase4 Study to Assess the Long-term Immunogenicity and Safety of Fourth Administration of BR JEV and to Investigate on Vaccine Interchangeability in Children Aged 6 Years Who Received 3 Doses With ENCEVAC or JEV-GCC
Latest Information Update: 15 Feb 2018
Price :
$35 *
At a glance
- Drugs Japanese encephalitis vaccine (Primary)
- Indications Japanese encephalitis
- Focus Pharmacodynamics
- Acronyms BR-JELITE
- Sponsors Boryung Pharmaceutical
- 08 Feb 2018 Results assessing long term immunogenicity of an initial booster dose published in the Vaccine
- 03 Feb 2017 Status changed from recruiting to completed.
- 28 Aug 2015 New trial record